多西紫杉醇联合卡培他滨治疗乳腺癌肝转移的临床观察  

Clinical observation on treatment of breast cancer liver metastases with docetaxel combined with capecitabine

作　　者：陈云兰[1] 赵金奇[1] 

机构地区：[1]云南省肿瘤医院干疗科,云南昆明650118

出　　处：《现代肿瘤医学》2012年第10期2082-2084,共3页Journal of Modern Oncology

摘　　要：目的:观察多西紫杉醇联合卡培他滨(TX)序贯卡培他滨单药维持治疗乳腺癌肝转移(breast cancerliver metastases,BCLM)的疗效和安全性。方法:回顾性分析TX方案治疗蒽环/和紫杉类药治疗的乳腺癌肝转移患者39例。全组共化疗230周期,中位周期数6周期(4-8周期)。有效者TX方案化疗6-8周期后序贯卡培他滨单药维持直至不能耐受或病情进展。结果:全组39例患者,4周期化疗后CR0例,PR20例(51.3%),SD14例(35.9%),PD 5例(12.8%),有效率51.3%,临床获益率87.2%。TTP 2.8-36.5月,中位TTP5月。结论:应用TX方案序贯卡培他滨维持治疗蒽环/和紫杉类治疗后乳腺癌肝转移疗效确切,毒副反应能耐受,值得临床推广。Objective：To study the efficacy and safety of docetaxel combined with capecitabine（TX） sequential capecitabine single-agent maintenance treatment for breast cancer liver metastases（BCLM）.Methods：The data of 39 breast cancer patients with liver metastasis were analyzed retrospectively treated by TX anthraquinone ring/and taxane combinations.All patients were treated by chemotherapy for 230 cycles,median cycle number was 6（4 to 8 cycles）.Results： Of 39 cases,CR 0 case,PR 20 cases（51.28%）,SD 14 cases（35.9%）,PD 5 cases（12.82%）,effictive rate was 51.28%,clinical benefit rate（87.18%）.Conclusion： Application of TX square sequential capecitabine maintenance treatment anthracene ring/and taxane combinations for liver breast cancer metastasis and side-effect are tolerated.

关 键 词：多西紫杉醇 卡培他滨 乳腺癌肝转移 联合化疗 

分 类 号：R737.9[医药卫生—肿瘤]